Last reviewed 2026-04-23 · How we verify

Bazedoxifene and conjugated estrogens

Bazedoxifene and conjugated estrogens is a Selective Estrogen Receptor Modulator (SERM) combination Small molecule drug developed by Wyeth is now a wholly owned subsidiary of Pfizer. It is currently in Phase 2 development for Moderate to severe vasomotor symptoms associated with menopause, Prevention of postmenopausal osteoporosis. Also known as: BZA+CE.

Bazedoxifene is a selective estrogen receptor modulator (SERM) that provides estrogen-like benefits in bone and lipid metabolism while blocking estrogen effects in breast tissue, combined with conjugated estrogens for menopausal symptom relief.

Bazedoxifene is a selective estrogen receptor modulator (SERM) that provides estrogen-like benefits in bone and lipid metabolism while blocking estrogen effects in breast tissue, combined with conjugated estrogens for menopausal symptom relief. Used for Moderate to severe vasomotor symptoms associated with menopause, Prevention of postmenopausal osteoporosis.

At a glance

Mechanism of action

Bazedoxifene acts as a SERM, selectively activating estrogen receptors in bone and cardiovascular tissues to maintain bone density and lipid profiles while antagonizing estrogen receptors in breast tissue to reduce proliferation risk. The conjugated estrogens component addresses vasomotor symptoms and other menopausal manifestations. This combination aims to provide the therapeutic benefits of hormone therapy while mitigating breast cancer risk.

Approved indications

• Moderate to severe vasomotor symptoms associated with menopause
• Prevention of postmenopausal osteoporosis

Common side effects

• Hot flashes
• Vaginal bleeding/spotting
• Breast tenderness
• Headache
• Leg cramps

Key clinical trials

• Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers (EARLY_PHASE1)
• Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens (PHASE2)
• Raising Insulin Sensitivity in Post Menopause (EARLY_PHASE1)
• The PROMISE Study: Duavee in Women With DCIS (PHASE2)
• Advancing Postmenopausal Preventive Therapy (PHASE2)
• Affect of Duavive on Mood & Anxiety Symptoms (PHASE1)
• Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee (PHASE4)
• Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bazedoxifene and conjugated estrogens CI brief — competitive landscape report
• Bazedoxifene and conjugated estrogens updates RSS · CI watch RSS
• Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI

Frequently asked questions about Bazedoxifene and conjugated estrogens

Related

• Drug class: All Selective Estrogen Receptor Modulator (SERM) combination drugs
• Target: All drugs targeting Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
• Manufacturer: Wyeth is now a wholly owned subsidiary of Pfizer — full pipeline
• Therapeutic area: All drugs in Women's Health / Endocrinology
• Indication: Drugs for Moderate to severe vasomotor symptoms associated with menopause
• Indication: Drugs for Prevention of postmenopausal osteoporosis
• Also known as: BZA+CE
• Compare: Bazedoxifene and conjugated estrogens vs similar drugs
• Pricing: Bazedoxifene and conjugated estrogens cost, discount & access